Table 3.

Binding Data for N-substituted analogues of 1^a

Compd	R	SERT Ki ± SEM (nM)	NET Ki ± SEM (nM)	Ki(NET)/Ki (SERT)
38b	H	5.04±0.176	880±12.4	174.6
39		93.4±7.83	69.8%c	>100
40		118±8.46	60.4% c	>100
41		61.6±6.19	276±41.1	4.5
42		40.9±3.51	179±17.7	4.4
43		25.1±2.03	448±24.8	17.8
44		57.9±8.44	265±37.0	4.5
45		22.8±2.29	62.9% c	>100
46		97.2±1.54	1380±162	14.2
47		152±9.25	28.1% c	>100
48		404±26.3	31.2% c	>100
49		98.8±13.3	272±48.5	2.7
50		19.0±2.65	60.3% c	>100
51		30.2±4.29	65.1% c	>100
53		53.1±3.0	1300±152	24.5
55		48.5±5.24	5090±749	105
57		114±11.1	20.2% c	>100
60		47.2±5.54	1020±67.4	21.6

^aThese novel analogues were assessed by radioligand binding displacement of [³H]S-1 (for SERT) and [³H]nisoxetine (for NET) in rat brain stem and frontal cortex, respectively;³⁵

^bPublished compound.^4,7,30

^c% Displacement at 10 µM.